GHDX: Summary for Genomic Health, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:15am EST - Canadian Markets open in 3 hours and 15 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Genomic Health Inc. (GHDX)

On Feb 9: 17.18 USD 0.00 (0.00%)

MORE ON GHDX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Genomic Health, Inc. (NGM:GHDX) Delayed quote data

Last Trade:	17.18 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	17.18
Open:	N/A
Bid:	N/A
Ask:	17.73 x 300
1y Target Est:	21.73

Day's Range:	N/A - N/A
52wk Range:	15.81 - 27.22
Volume:	0
Avg Vol (3m):	171,692
Market Cap:	491.97M
P/E (ttm):	N/A
EPS (ttm):	-0.33
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add GHDX to Portfolio

Download Data

HEADLINES

•	New Star Analyst Rankings for Genomic Health, Inc.
	StarMine (Thu, Feb 4)

•	GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
	EDGAR Online (Wed, Feb 3)

•	Genomic Health Announces Year-End 2009 Financial Results
	PRNewswire (Wed, Feb 3)

•	Q4 2009 Genomic Health, Inc. Earnings Release - After Market Close
	CCBN (Wed, Feb 3)

•	Genomic Health to Announce Fourth Quarter and Year-End 2009 Financial Results and Host Conference Call on Wednesday, February 3
	PRNewswire (Wed, Jan 27)

•	5 Diagnostics Stocks Get 2010 Buy Rating From Natixis Bleichroeder Expert Industry Analyst
	Wall Street Transcript (Mon, Jan 25)

•	Gene discovery may help guide breast cancer care
	at Reuters (Sun, Jan 24)

•	Good News from Genomic Health
	Zacks.com (Fri, Jan 22)

•	Genomic Health upgraded by Piper Jaffray
	Briefing.com (Fri, Jan 22)

•	Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
	PRNewswire (Thu, Jan 21)

•	Genomic Health Announces Publication of Data Demonstrating that the Oncotype DX(R) Breast Cancer Test Significantly Influences Breast Cancer Treatment
	PRNewswire (Tue, Jan 12)

More Headlines for GHDX...

ANALYST

EPS Est (next year) (Dec-10) :	0.06
EPS Est (in 2 years) (Dec-11) :	0.36
Avg Rec (current)*:	2.5
PEG Ratio:	18.82

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Genomic Health, Inc. operates as a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions.

Full Company Profile

Add to Portfolio

Email to a Friend

•